Should Xilio Therapeutics Inc (NASDAQ: XLO) Revive After A -110.95% Drop From Highs?

During the last session, Xilio Therapeutics Inc (NASDAQ:XLO)’s traded shares were 3.46 million, with the beta value of the company hitting -0.05. At the end of the trading day, the stock’s price was $1.37, reflecting an intraday gain of 38.38% or $0.38. The 52-week high for the XLO share is $2.89, that puts it down -110.95 from that peak though still a striking 64.23% gain since the share price plummeted to a 52-week low of $0.49. The company’s market capitalization is $60.21M, and the average intraday trading volume over the past 10 days was 0.51 million shares, and the average trade volume was 154.43K shares over the past three months.

Xilio Therapeutics Inc (XLO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. XLO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Xilio Therapeutics Inc (NASDAQ:XLO) trade information

Xilio Therapeutics Inc (XLO) registered a 38.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 38.38% in intraday trading to $1.37, hitting a weekly high. The stock’s 5-day price performance is 59.30%, and it has moved by 82.67% in 30 days. Based on these gigs, the overall price performance for the year is -34.76%. The short interest in Xilio Therapeutics Inc (NASDAQ:XLO) is 0.1 million shares and it means that shorts have 0.76 day(s) to cover.

The consensus price target of analysts on Wall Street is $7, which implies an increase of 80.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, XLO is trading at a discount of -410.95% off the target high and -410.95% off the low.

Xilio Therapeutics Inc (XLO) estimates and forecasts

Statistics show that Xilio Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Xilio Therapeutics Inc (XLO) shares have gone up 26.85% during the last six months, with a year-to-date growth rate more than the industry average at 54.68% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 59.00% this quarter and then jump 59.40% in the quarter after that.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.3M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 3.3M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -44.91%. While earnings are projected to return 54.80% in 2024.

XLO Dividends

Xilio Therapeutics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders

Xilio Therapeutics Inc insiders own 40.93% of total outstanding shares while institutional holders control 30.22%, with the float percentage being 51.17%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the largest shareholder of the company, while 35.0 institutions own stock in it. As of 2024-06-30, the company held over 3.79 million shares (or 13.5618% of all shares), a total value of $3.59 million in shares.

The next largest institutional holding, with 3.0 million shares, is of ROCK SPRINGS CAPITAL MANAGEMENT LP’s that is approximately 10.7595% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.85 million.